R3421: Additional Phase IIa data

Data from both portions of the double-blind, dose-ranging Phase IIa Study 201 trial in 99 evaluable patients showed that once-daily 40, 80, 120, 160 and 240 mg BCX4208 significantly reduced sUA levels...